摘要
目的 探讨慢性心力衰竭 (心衰 )患者是否存在补体激活以及补体激活与心衰患者预后的关系。方法 检测 4 4例心衰患者 (心衰组 )和 16例性别、年龄匹配的健康人 (对照组 )血浆补体经典激活途径产物C4d、替代激活途径产物Bb、终末共同途径产物C3bc和补体激活终末复合物C5b 9浓度。心衰组平均随访 (13± 3)个月 ,观察患者是否因心功能恶化而住院治疗或因心功能恶化死亡。结果 (1)心衰组血浆C4d、Bb、C3bc和C5b 9浓度均显著高于对照组 ;(2 )心衰组中 ,血浆C5b 9浓度低于中位数的心衰患者与血浆C5b 9浓度高于中位数的心衰患者相比 ,后者心功能较差 ,因心功能恶化住院和死亡的例数较多。结论 心衰患者补体系统被激活 ,血浆C5b 9浓度显著提高与心衰患者心功能和预后较差有关 ,提示补体可能成为治疗慢性心衰的一个新的靶点。
Objective To determine whether the complement system is activated and its relation to clinical outcome in patients with congestive heart failure (CHF). Methods The plasma levels of products of complement activation C4d (classic pathway), Bb (alternative pathway), 3bc (final common pathway) and C5b-9 (terminal complement complex) were measured in forty-four patients with CHF and sixteen normal volunteers with the age and sex matched. Forty-one patients with CHF were followed up for (13±3) months to determine the combined clinical outcomes (hospitalization with worsening heart failure or death). Results (1)The plasma levels of C4d,Bb,C3bc and C5b-9 in patients with CHF were significantly higher than those in normal volunteers. (2) Significantly more of the patients with CHF with higher levels of C5b-9 (higher than 50th percentile ) had worse left ventricular function and adverse clinical outcomes compared with the patients with CHF with lower levels (lower than 50th percentile). Conclusion There was an activation of complement system and an association between high levels of C5b-9 and adverse clinical events in patients with CHF, which suggested that complement might be added to the list of possible therapeutic targets.
出处
《中华心血管病杂志》
CAS
CSCD
北大核心
2004年第2期135-137,共3页
Chinese Journal of Cardiology
基金
广州市科委攻关项目 (2 0 0 0 Z 110 0 2 )
